Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
DESCRIPTION (provided by applicant): Morbidity and mortality due to infections with Toxoplasma gondii is an increasing problem in the HIV infected population. Management of toxoplasmosis in these patients is complicated by a high incidence of side effects with the most commonly used compounds and the inactivity of these compounds against the latent stage of the parasite. Hence, there is a continuing need to define novel therapeutic targets and develop new therapeutic agents for this pathogen. One feature of the basic metabolism of these organisms which has not been fully exploited for chemotherapy is the characteristics of their adenosine kinase and its unique specificity in the activation of "subversive" substrates". Results from our laboratory indicate that the parasite, but not the host, adenosine kinase can uniquely phosphorylate certain 6-substituted purine nucleosides as "subversive" substrates and thereby selectively kill T. gondii in vitro and extend the life span of infected mice. Therefore, T. gondii adenosine kinase was cloned, overexpressed and purified. Structure activity relationships as well as comparative metabolic and molecular studies indicate that T. gondii adenosine kinase is indeed substantially different from that of the host in substrate specificity, structure and other characteristics. The purpose of this application is to extend our studies to further characterize the T. gondii adenosine kinase and to use the information gained to develop potent and selective subversive substrates as potential anti-toxoplasmic agents. This approach may well apply to other opportunistic infections which share with toxoplasma this unique feature of purine analogue metabolism. The Specific Aims are: Aim 1: Detailed studies of the cloned T. gondii adenosine kinase. Aim 2: Crystallization and resolution of the three dimensional structures of the enzyme with bound 6-substituted subversive substrates. Aim 3. Molecular modeling studies for the rational design of 6-substituted subversive substrates. Aim 4: Chemical synthesis and enzymatic evaluation of rationally designed 6-substituted subversive substrates. Aim 5: Evaluate promising rationally designed 6-substituted subversive substrates as potential anti-toxoplasmosis agents in vitro and in vivo. Aim: 6. Determine the mechanism of selective toxicity of active compounds. These studies will utilize the complementary strengths of the investigators in a collaborative, integrated effort to achieve these goals.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
01-July-2004
Project End Date
30-June-2009
Budget Start Date
01-July-2007
Budget End Date
30-June-2009
Project Funding Information for 2007
Total Funding
$498,669
Direct Costs
$405,681
Indirect Costs
$92,988
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Allergy and Infectious Diseases
$498,669
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI052838-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI052838-04
Patents
No Patents information available for 5R01AI052838-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI052838-04
Clinical Studies
No Clinical Studies information available for 5R01AI052838-04
News and More
Related News Releases
No news release information available for 5R01AI052838-04
History
No Historical information available for 5R01AI052838-04
Similar Projects
No Similar Projects information available for 5R01AI052838-04